OSE Immunotherapeutics (OSE) Stock Overview
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OSE Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
OSE Immunotherapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.31 |
| 52 Week High | €7.70 |
| 52 Week Low | €4.23 |
| Beta | 0.51 |
| 1 Month Change | -16.76% |
| 3 Month Change | -19.10% |
| 1 Year Change | -32.52% |
| 3 Year Change | -29.48% |
| 5 Year Change | -68.29% |
| Change since IPO | -58.74% |
Recent News & Updates
Recent updates
OSE Immunotherapeutics SA's (EPA:OSE) Shares Bounce 33% But Its Business Still Trails The Industry
Jul 30
OSE Immunotherapeutics SA's (EPA:OSE) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 04The Strong Earnings Posted By OSE Immunotherapeutics (EPA:OSE) Are A Good Indication Of The Strength Of The Business
Apr 05We Think OSE Immunotherapeutics (EPA:OSE) Can Stay On Top Of Its Debt
Apr 04Revenues Working Against OSE Immunotherapeutics SA's (EPA:OSE) Share Price
Feb 17OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 19Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings
Oct 04Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?
May 23We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
May 11Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher
Mar 16Shareholder Returns
| OSE | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -9.3% | 1.0% | 1.2% |
| 1Y | -32.5% | 303.3% | 1.2% |
Return vs Industry: OSE underperformed the French Biotechs industry which returned 292.1% over the past year.
Return vs Market: OSE underperformed the French Market which returned 0.1% over the past year.
Price Volatility
| OSE volatility | |
|---|---|
| OSE Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: OSE has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: OSE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 64 | Marc Le Bozec | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
| OSE fundamental statistics | |
|---|---|
| Market cap | €96.68m |
| Earnings (TTM) | -€32.52m |
| Revenue (TTM) | €1.78m |
Is OSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSE income statement (TTM) | |
|---|---|
| Revenue | €1.78m |
| Cost of Revenue | €0 |
| Gross Profit | €1.78m |
| Other Expenses | €34.30m |
| Earnings | -€32.52m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,824.86% |
| Debt/Equity Ratio | 106.4% |
How did OSE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 15:42 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OSE Immunotherapeutics SA is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Roba | Degroof Petercam |
| David Seynnaeve | Degroof Petercam |
| Jyoti Prakash | Edison Investment Research |